A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Greenphire Launches, EnvisiX, A New Clinical Trial Budget Build and Negotiation Solution

   by Greenphire, Contributor    166    Comments 0

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Today, Greenphire, the global leader in financial lifecycle management for clinical trials, announced the launch of a new budget development solution, EnvisiX, to address the budgeting challenges experienced by global sponsors and CROs during study start-up.

Integrated with eClinicalGPS, Greenphire’s industry-leading site payment solution, enables unprecedented simplicity and efficiency throughout a trial from budget creation and negotiation to management, execution, and tracking of global investigator grants.

Greenphire, the global leader in financial lifecycle management for clinical trials, today announced the launch of EnvisiX to address the budgeting challenges experienced by global sponsors and CROs during study start-up. The new budget development solution streamlines trial initiation for sponsors and CROs and eliminates guesswork during the budgeting process to deliver a smarter, more efficient workflow.

EnvisiX seamlessly integrates with eClinicalGPS, Greenphire’s industry-leading site payment solution, enabling unprecedented simplicity and efficiency throughout a trial from budget creation and negotiation to management, execution, and tracking of global investigator grants.

EnvisiX will enable sponsors and CROs to:

  • Have access to the most robust and contemporary investigator grant payment data in the industry
  • Simplify and streamline the budget creation and negotiation workflow for improved collaboration, transparency and management of rates, adjustments, adjudications, approvals and more
  • Benefit from an integration with the industry leading site payment solution, eClinicalGPS, providing a unified workflow from budget build and negotiation through payment execution and analysis
  • Access expert teams of local negotiators with country-level budget knowledge and international lawyers providing in-country consultation and regulatory oversight and guidance
  • Achieve or beat ‘First Patient In’ milestone targets by eliminating administrative burden and reducing cycle times

“For years, sponsors and CROs have expressed dissatisfaction with their study start-up processes. We have developed EnvisiX as a direct response to frustrations with the current workflows and solutions available in the market today,” said Kyle Cunningham, Chief Product Officer at Greenphire. “Our mission was to ensure that EnvisiX provides our customers with a streamlined and user friendly experience for building a budget and ultimately to enable maximized confidence, defensibility and end-to-end efficiency via a direct integration and feedback loop with eClinicalGPS, the industry’s leading site payment solution."

To learn more about EnvisiX, visit us at https://greenphire.com/budgeting/.

“Greenphire is dedicated to engineering workflow and data solutions that transform business processes, reducing administrative burden and improving process effectiveness at each step of the clinical trial,” said Jim Murphy, Greenphire CEO. “With EnvisiX, stakeholders gain visibility and control over historically manual and fragmented budget build and negotiation workflows, ensuring improved speed and accuracy along the way."

Murphy will Chair the on-demand session “Optimizing Study Start Up Processes: Site Selection, Budgeting & Contracting” at the DIA 2020 Virtual Meeting beginning on June 14. To attend, visit https://bit.ly/2SXq0yr.

Share this:              
A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D
 

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *